Europe Skin Grafting System Market

The skin grafting system market in Europe is expected to grow from US$ 347.09 million in 2021 to US$ 557.98 million by 2028; it is estimated to grow at a CAGR of 7.0% from 2021 to 2028.

Skin grafts are ideally preferred post-surgery for skin cancers. Skin grafts are generally referred for local postoperative radiotherapy (PORT) to ensure the closure of surgical beds created during radiotherapy. According to Cancer Research UK, ~15,400 new melanoma skin cancer cases are registered in the UK every year, accounting for 42 new cases every day.

Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, and 32 cases per 100,000 people are expected to be recorded by 2035. According to the recent statistics published by the International Agency for Research on Cancer, 19.3 million new cancer cases were registered in 2020, excluding 18.1 million nonmelanoma skin cancer cases. Thus, an increase in the prevalence of skin cancer is propelling the demand for skin grafting systems.

Diabetes is among the most common health conditions prevalent globally. According to the International Diabetes Federation’s (IDF) Diabetes Atlas Ninth edition 2019, ~463 million adults suffer from diabetes worldwide. The prevalence is estimated to be 700 million by 2045, and nearly 79% of adults will be affected by diabetes in low-and-middle incomes countries worldwide. Among the prevalence of diabetes, the proportion of type 2 diabetes is increasing faster. According to the IDF, 374 million people are at risk of developing type 2 diabetes in the future globally. Among diabetic patients, wound healing is prolonged, which increases the risk of skin infections if it is not healed within a particular time. Further, 25% of diabetic patients are likely to develop foot ulcers once in their lifetime that often need advanced diabetic wound care. Therefore, there is a high demand for skin grafts and related systems to treat or cover diabetic foot ulcers by eliminating the chances of contracting skin infections. Also, diabetic foot ulcers are a common complication that is not well controlled. Resulting from poor glycemic control, underlying neuropathy, peripheral vascular disease, or poor foot care, diabetic foot ulcers can lead to osteomyelitis of the foot and amputation of the lower extremities. Skin grafts are used to treat nonhealing ulcers and foot parts and prevent further complications. Thus, the high prevalence rate of skin cancer and diabetes is driving the growth of the skin grafting system market.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe skin grafting system market in the coming years. The market is expected to grow at a good CAGR during the forecast period.

Europe Skin Grafting System

Market Revenue and Forecast to 2028 (US$ Million)

Europe Skin Grafting System Market Segmentation

The Europe skin grafting system market is segmented on the basis of product type, type, wound type, end user, and country. The market, based on product type, is segmented into dermatomes, wound debridement devices, skin graft mesher equipment and accessories, and others. The wound debridement devices segment held the largest share of the market in 2021. Based on type, the Europe skin grafting system market is bifurcated into autograft and allograft. The autograft segment held a larger share of the market in 2021 and is expected to hold a significant share of the market during the forecast period. Based on wound type, the market is segmented into burns, chronic wounds, traumatic wounds, surgical wounds, and others. The burns segment is expected to hold the largest market share during the forecast period. Based on end user, the Europe skin grafting system market is segmented into hospitals, ambulatory surgical centers, and specialty clinics. The hospitals segment held the largest share of the market and is expected to register the highest CAGR during the forecast period. Based on country, the Europe skin grafting system market is segmented into France, Germany, Italy, Spain, the UK, and the Rest of Europe.

Aygun Surgical Instruments Co., Inc.; De Soutter Medical; Humeca BV; Integra Lifesciences Holdings Corp.; Lutz GmbH & Co. KG; Smith & Nephew; Stryker Corp.; and Zimmer Biomet are among the leading companies in the Europe skin grafting system market.